June 4, 2021 07:00 AM EDTUpdated 07:19 AM
FDA+
Coronavirus

Re­gen­eron con­tin­ues reign atop the Covid treat­ment field with ex­pand­ed EUA for low­er dose sub­cu­ta­neous ver­sion of mAb cock­tail

Zachary Brennan

Senior Editor

The FDA on Fri­day au­tho­rized a new, low­er-dose ver­sion of Re­gen­eron’s Covid-19 mon­o­clon­al an­ti­body cock­tail for those with Covid-19 who are at high-risk of pro­gress­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times